Highlights

  • Emyria has recruited 31 additional therapists, with Training commencing 27 November 2026, designed to meet expected growth in patient treatment volumes across the national Empax network in 2027.
  • Of the 31 recruits, 18 meet TGA Lead Therapist eligibility criteria, and 10 are psychologists specifically to support DVA-funded treatments for eligible Australian Veterans.
  • The expanded workforce will support three Revenue streams: reimbursed patient treatments, DVA-funded Veteran treatments, and pharmaceutical-sponsored clinical trials.
  • Emyria holds 18 treatment beds across five sites nationally; therapist availability, not bed numbers, is currently the binding constraint on treatment capacity.

Emyria Limited (ASX:EMD) has announced the recruitment of 31 additional therapists to its national Empax clinical network, with specialised in-house training commencing 27 November 2026. The recruitment is designed to increase patient treatment capacity across Emyria's five-clinic network in Perth, Brisbane, and Sydney ahead of anticipated growth in treatment volumes in 2027. Emyria delivers evidence-based intensive mental health care for patients with post-traumatic stress disorder (PTSD) and treatment-resistant depression (TRD) who have not responded adequately to standard care.

Therapist Numbers as the Key Capacity Constraint

Emyria's treatment model involves multi-hour, therapist-attended sessions for each patient. Unlike conventional medical treatments, the company's PTSD and TRD programmes require trained therapists to be present throughout each treatment, meaning therapist availability directly determines how many patients can be treated at any point in time. The company has 18 treatment beds across its five clinic sites, but it has identified therapist numbers — not physical capacity — as the current constraint on the number of patients it can treat. The addition of 31 trained therapists will therefore unlock the latent capacity within existing clinic infrastructure without the need for immediate additional Facility investment.

On completion of training and supervised onboarding in the first quarter of 2027, the expanded workforce is expected to increase the number of treatments delivered across the Empax network. The 22 therapists from Perth, six from Brisbane, and three from Sydney will distribute the capacity increase across the company's three primary cities of operation.

DVA Programme and TGA Lead Therapist Eligibility

A notable feature of this recruitment is the inclusion of 10 psychologists specifically selected to meet the Department of Veterans' Affairs (DVA) workforce requirements for treating eligible Australian Veterans. DVA-funded treatments for PTSD are a distinct revenue stream for Emyria, with specific therapist qualification and supervision requirements that differ from the standard reimbursed patient pathway. By expanding the pool of psychologists meeting DVA requirements, Emyria is positioning to capture anticipated growth in government-funded Veteran treatment volumes in 2027.

Of the remaining recruits, 18 meet the Therapeutic Goods Administration (TGA) Lead Therapist eligibility criteria, which are relevant for the company's PTSD treatment programmes using regulated therapeutic substances. The TGA Lead Therapist designation requires specific training, supervision standards, and registration requirements, and governs who may administer or supervise certain aspects of therapeutic psychedelic-assisted treatment sessions. Building the pool of TGA-eligible clinicians is critical to scaling the company's licensed treatment capacity.

Revenue Streams and 2027 Growth Strategy

The expanded therapist workforce is expected to support revenue growth across three established clinical delivery channels. The first is reimbursed patient treatments, where patients access Emyria's PTSD and TRD programmes through established reimbursement pathways. The second is DVA-funded Veteran treatments, which are funded by the Australian Government for eligible Veterans through DVA. The third is pharmaceutical-sponsored clinical trials, where Emyria's clinical infrastructure and trained workforce are made available to international pharmaceutical partners seeking to run sponsor-funded research programmes through the Empax network.

Emyria describes its strategic shift for 2027 as moving from establishing national clinical infrastructure to scaling patient treatment volumes. The recruitment of 31 therapists is characterised as a capital-efficient approach to growth because it increases utilisation of the already-sunk costs of clinic establishment and bed infrastructure, rather than requiring further Capital outlay on new facilities to increase capacity.

Key Insights

The recruitment of therapists rather than beds is a capital-efficient approach to expanding treatment capacity, leveraging existing clinic infrastructure that was established at significant prior cost without requiring further facility investment.

The specific inclusion of 10 psychologists to meet DVA requirements reflects Emyria's strategy to capture government-funded Veteran treatment growth as a distinct revenue stream, potentially offering more stable and contracted Demand than purely market-funded pathways.

The addition of 31 therapists could materially increase the number of patients treated per period if onboarding and training proceed as planned, with improved clinic utilisation directly driving commercial activity and revenue.